Abstract
Background: Baseline outcome risk can be an important determinant of absolute treatment benefit and has been used in guidelines for “personalizing” medical decisions. We compared easily applicable risk-based methods for optimal prediction of individualized treatment effects. Methods: We simulated RCT data using diverse assumptions for the average treatment effect, a baseline prognostic index of risk, the shape of its interaction with treatment (none, linear, quadratic or non-monotonic), and the magnitude of treatment-related harms (none or constant independent of the prognostic index). We predicted absolute benefit using: models with a constant relative treatment effect; stratification in quarters of the prognostic index; models including a linear interaction of treatment with the prognostic index; models including an interaction of treatment with a restricted cubic spline transformation of the prognostic index; an adaptive approach using Akaike’s Information Criterion. We evaluated predictive performance using root mean squared error and measures of discrimination and calibration for benefit. Results: The linear-interaction model displayed optimal or close-to-optimal performance across many simulation scenarios with moderate sample size (N = 4,250; ~ 785 events). The restricted cubic splines model was optimal for strong non-linear deviations from a constant treatment effect, particularly when sample size was larger (N = 17,000). The adaptive approach also required larger sample sizes. These findings were illustrated in the GUSTO-I trial. Conclusions: An interaction between baseline risk and treatment assignment should be considered to improve treatment effect predictions.
Original language | English |
---|---|
Article number | 74 |
Journal | BMC Medical Research Methodology |
Volume | 23 |
Issue number | 1 |
DOIs | |
Publication status | Published - 28 Mar 2023 |
Bibliographical note
Funding Information:This work has been performed in the European Health Data and Evidence Network (EHDEN) project. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA.
Publisher Copyright:
© 2023, The Author(s).